

# CORRIGENDUM

DOI: 10.3892/ijo.2021.5212

## Cyclophilin D modulates cell death transition from early apoptosis to programmed necrosis induced by honokiol

WEI TIAN, DONG XU, WEIDONG HAN, HAIFEI HE, HONGKE CAI, HAILONG CHEN, MEIQI ZHOU, JIANI CHEN and YONG-CHUAN DENG

Int J Oncol 42: 1654-1663, 2013; DOI: 10.3892/ijo.2013.1863

Subsequently to the publication of the above article, the authors have realized that the printed version of Fig. 6 on p. 1661 contained some mistakes. Potential anomalies regarding this figure concerning the duplication of data both within Fig. 6 and comparing data between Figs. 5 and 6 were also drawn to our attention by an interested reader. Specifically, the authors realized that the bands of BCL-xl were erroneously selected from the GAPDH dataset during the process of compiling this figure. The authors subsequently found that the original photographs of these western blot bands had been lost during the time period that had elapsed since these experiments were completed. In order to corroborate the results, the authors repeated the contentious experiments shown in Fig. 6 and obtained similar results, thereby corroborating the results and conclusions reported in this study.

A revised version of Fig. 6, containing the newly obtained data, is shown below. The errors made with the assembly of Fig. 6 originally did not have an adverse bearing on the overall conclusions reported in this study. The authors are grateful to the Editor of *International Journal of Oncology* for allowing them the opportunity to publish this Corrigendum, and all of the authors agree to the publication of this Corrigendum. The authors sincerely apologize for their errors, and apologize to the readership of the Journal for any inconvenience caused.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.




Figure 6. PTEN overexpression paralleling with cell death mode transition. Protein expression of Bcl-2, Bcl-xl, PTEN and GAPDH after (A) time- and (B) dose-gradient treatments with HNK was determined with western blot analysis.